[Combination therapy of CPT-11, a camptothecin derivative, with various antitumor drugs against L 1210 leukemia].
Antitumor effect of CPT-11 in combination with cyclophosphamide (CY), nimustin hydrochloride (AC-NU), thio-TEPA (TESPA), methotrexate (MTX), 5-fluorouracil (5-FU), cytosine arabinoside (ara-C), thioinosine (6-MPR), adriamycin (ADM), bleomycin (BLM), mitomycin C (MMC), actinomycin D (ACT-D), vincristine sulfate (VCR), etoposide (VP-16) or cisplatin (CDDP) against L 1210 murine leukemia was investigated. The combination treatment of CPT-11 with CY, ACNU, ADM, CDDP, TESPA and ACT-D showed synergistic effects and significantly prolonged the survival time of L 1210-inoculated mice compared with CPT-11 alone or antitumor drug alone. Although the combination with 5-FU, 6-MPR, VP-16, MMC or VCR had synergistic effect for some schedules exceptionally with ara-C, MTX or BLM had slight synergistic effect against L 1210.
Furuta
T
T
Yakult Central Institute for Microbiological Research, Tokyo, Japan.
Yokokura
T
T
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D000077146:Irinotecan; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage; D051379:Mice; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D013868:Thioinosine / Q000008:administration & dosage
D000972:Antineoplastic Agents, Phytogenic; D008937:Mitomycins; D013868:Thioinosine; D016685:Mitomycin; D000077146:Irinotecan; D003520:Cyclophosphamide; D002945:Cisplatin; D002166:Camptothecin; D008727:Methotrexate